To include your compound in the COVID-19 Resource Center, submit it here.

Gemphire sinks on Phase IIb gemcabene data in hypercholesterolemia

Gemphire Therapeutics Inc. (NASDAQ:GEMP) plummeted $8.73 (47%) to $9.93 on Monday after it reported preliminary Phase IIb data for its lead candidate gemcabene (CI-1027) to treat hypercholesterolemia in which

Read the full 295 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE